Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Long-Term Epilepsy Outcomes in Children With a History of Perinatal Stroke

NCT07898397 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-04-28
Last updated
2026-10-27

Condition(s) studied

Perinatal StrokeEpilepsyPost-Stroke Epilepsy

Study summary

Perinatal stroke is a rare condition affecting approximately 20-40 births per 100,000. It may be ischemic or hemorrhagic and can occur before or around birth, with diagnosis sometimes delayed until motor or cognitive symptoms emerge. Potential long-term consequences include motor deficits, cognitive and learning difficulties, language disorders, and epilepsy.

Post-stroke epilepsy is estimated to affect approximately 30% of children who experience perinatal stroke. Although neonatal outcomes are relatively well characterized, the long-term course of epilepsy in this population and the relationship between initial stroke characteristics and subsequent epilepsy outcomes remain insufficiently studied.

The primary objective of this retrospective, multicenter, observational study is to characterize the long-term course of epilepsy in children who experienced an ischemic or hemorrhagic stroke before 28 days of age.

Eligibility

Sex
ALL
Min age
5 Years
Max age
25 Years
Healthy volunteers
No
Inclusion Criteria: * Minors aged 5 to under 18 years or adults aged 18 to 25 years. * Patients who attended one of the two participating centers: Strasbourg University Hospitals or Necker Hospital (AP-HP). * Confirmed or suspected ischemic or hemorrhagic stroke occurring before 28 days of age. * During follow-up, presentation of criteria for focal epilepsy, infantile spasms, continuous spike-and-wave during sleep (CSWS), or Lennox-Gastaut syndrome. Exclusion Criteria: * Birth before 34 weeks of gestation. * Birth weight below 1,500 g. * Perinatal hypoxic-ischemic injury with residual MRI lesions. * Insufficient information in medical records. * Refusal to participate in the study.

Primary outcome measure(s)

  • Drug-Resistant Epilepsy at 6 Years of Age — At 6 years of age.
    Presence of drug-resistant epilepsy at six years of age, defined in the study protocol as requiring more than two treatments.
  • Adapted Schooling at 6 Years of Age — At 6 years of age.
    Attendance in a specialized educational setting (ULIS or IME) or absence of schooling at six years of age.

Trial sites (1)

FacilityCityRegionStatus
Service de Pédiatrie 1 - Hôpital de Hautepierre - CHU de Strasbourg, France Strasbourg France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07898397 on ClinicalTrials.gov ↗ ← All trials in France